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Introduction
The oral antihyperglycemic agent metformin was asso-
ciated with favorable outcome and smaller myocardial
infarct size in patients with diabetes undergoing percuta-
neous coronary interventions (PCI) for ST-segment eleva-
tion myocardial infarction (STEMI) [1,2]. However, these
findings have not been validated.
Objectives
To determine the effect of chronic metformin treatment
on cardiovascular morbidity and mortality in patients
with diabetes presenting with STEMI subsequently
undergoing PCI.
Methods
From January 2004 until June 2013, all consecutive criti-
cally ill patients undergoing primary PCI for STEMI at the
University Medical Center Groningen were included in a
registry and 1-year follow-up was obtained. Our primary
endpoint consisted of the composite endpoint of myocar-
dial infarction, target vessel and target lesion revasculariza-
tion, and all-cause mortality (MACE). The secondary
endpoint, myocardial infarction size, was estimated using
peak levels of creatine kinase (CK), the myocardial band of
CK (CK-MB), troponin T, and high-sensitive troponin T
(hs-troponin T). The effect of metformin on myocardial
infarct size from the 2004-2010 cohort has been reported
previously [1]. Therefore myocardial infarction size was
reported for patients admitted from 2011 until 2013 and
the combined 2004-2013 cohort.
Results
In total, 4776 consecutive patients underwent primary
PCI for STEMI, 719 (15%) diabetic patients were
included in the final analysis and 215 (30%) patients
used metformin at admission. MACE and mortality
rates were 21% and 12% for patients with diabetes, 23%
and 19% for metformin patients, 21% and 15% for
patients on sulfonylurea, and 30% and 20% for patients
on insulin, respectively. Metformin was not associated
with reduced risk for MACE (adjusted hazard ratio
(aHR): 1.19 (95% confidence interval (95%CI) 0.78-1.81),
P = 0.42) or survival benefit (aHR: 0.23 (CI95% 0.80-
2.51), P = 0.23) compared to diabetic patients not using
metformin. Insulin use was an independent predictor
for MACE (aHR 1.73 (CI95% 1.13-2.65), P = 0.01) and
all-cause mortality (aHR 1.81 (CI95% 1.03-3.21), P =
0.04). Baseline levels of CK, CK-MB, and hs-troponin T
were comparable between both groups. Median (inter-
quartile range) peak levels of CK, CK-MB, and hs-Tro-
ponin T were all non-significant lower in the metformin
group (table 1). When both cohorts were combined,
peak levels of CK, CK-MB, and troponin T were all sig-
nificantly lower in patients using metformin, as depicted
in table 1.
Conclusions
Chronic metformin use in patients presenting with
STEMI was associated with smaller infarct-size and not
with lower MACE and mortality rates, as compared to
other patients with diabetes.
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Table 1
2011-2013 cohort Combined 2004-2013 cohort
Peak value Metformin (n = 83) No metformin (n = 72) P-value Metformin (n = 254) No metformin (n = 537) P-value
CK (U/L) 846 (297-2317) 1083 (481-3005) 0.25 1000 (297-3594) 1371 (597-3034) 0.01
CK-MB (U/L) 112 (52-211) 120 (60-309) 0.33 138 (52-256) 174 (74-310) < 0.01
Hs-Troponin T (ng/L) 2175 (592-5337) 2076 (912-5512) 0.70
Troponin T (μg/L) 2.53 (0.55-7.63) 3.93 (1.39-8.67) 0.01
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